PlainRecalls
FDA Drug Moderate Class II Ongoing

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 30 count (NDC 70934-309-30); b) 60 count (NDC 70934-309-60); c) 90 count (70934-309-90); d) 120 count (NDC 70934-309-98) bottles, Rx Only, Time-Cap Labs Inc. Repackaged by Northwind Pharmaceuticals North Blenheim, NY 12131

Reported: November 11, 2020 Initiated: October 8, 2020 #D-0057-2021

Product Description

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 30 count (NDC 70934-309-30); b) 60 count (NDC 70934-309-60); c) 90 count (70934-309-90); d) 120 count (NDC 70934-309-98) bottles, Rx Only, Time-Cap Labs Inc. Repackaged by Northwind Pharmaceuticals North Blenheim, NY 12131

Reason for Recall

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)

Details

Recalling Firm
Denton Pharma, Inc.
Units Affected
a) 684; b) 432; c) 3668; d) 2029 bottles
Distribution
Indiana - Nationwide.
Location
North Blenheim, NY

Frequently Asked Questions

What product was recalled?
Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 30 count (NDC 70934-309-30); b) 60 count (NDC 70934-309-60); c) 90 count (70934-309-90); d) 120 count (NDC 70934-309-98) bottles, Rx Only, Time-Cap Labs Inc. Repackaged by Northwind Pharmaceuticals North Blenheim, NY 12131. Recalled by Denton Pharma, Inc.. Units affected: a) 684; b) 432; c) 3668; d) 2029 bottles.
Why was this product recalled?
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)
Which agency issued this recall?
This recall was issued by the FDA Drug on November 11, 2020. Severity: Moderate. Recall number: D-0057-2021.